Le Lézard
Classified in: Health
Subjects: NEW PRODUCTS/SERVICES, PARTNERSHIPS, HEALTH

Benefits by Design (BBD) Inc. Partners with Telemedicine Company GOeVisit to innovate access to medical care


VANCOUVER, British Columbia, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Benefits By Design (BBD), a third party administrator that connects Canadian businesses with benefits and workplace solutions, has partnered with MyCare MedTech Inc., a Canadian telehealth company offering medical care through its platform, GOeVisit. GOeVisit provides virtual consultations with medical providers for minor illnesses 24/7 from coast to coast. The partnership offers BBD groups an innovative way to access medical care for minor illnesses without having to leave home or office and without experiencing long wait times.

"Canadians are ready to take control of their healthcare," says Liz Bryant, Chief Operating Officer of MyCare MedTech Inc., "and want alternatives to waiting for care for minor illnesses. Two thirds of Canadians surveyed want to access care the way they use so many other services: through technology. BBD continues to show industry leadership by making GOeVisit available to their clients."

GOeVisit uses the same technology people already use daily to turn a computer, smartphone, or tablet into a private, face-to-face medical visit that can also be accessed through a free mobile app. GOeVisit's medical team can diagnose, treat, and prescribe for more than 80 minor illnesses ranging from coughs, colds and flu, to general medical concerns, minor injuries and pediatric care. If a prescription is required, it can be sent to the pharmacy of the client's choice or can be delivered next business day anywhere in Canada.

BBD's Managing Partner Mike McClenahan says, "We know many working Canadians lack regular, dependable access to a family physician. GOeVisit bridges that gap to treat minor illnesses for plan members and their dependents, no matter where they're located. That makes this service a perfect fit as BBD continues to find new ways to help working Canadians." 

About MyCare MedTech Inc.
MyCare MedTech Inc. is a Canadian telemedicine company with offices in Calgary, AB and Vancouver, BC. For more information, visit http://www.goevisit.com and watch our video at https://www.youtube.com/watch?v=T4dMy1rYRiw

Aaryn Bryant
MyCare MedTech Inc.
403.671.5979
[email protected] 

About Benefits by Design
BBD helps working Canadians connect with group benefits and workplace solutions that grow business and support good health. See BBD's culture in action at #BBDWorkplace, join the conversation @BBDCanada, or visit www.bbd.ca for more information.

Julie Einarson
Benefits by Design (BBD) Inc.
613.530.2422
[email protected]


These press releases may also interest you

at 08:25
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:19
Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), a global leader in contract development and manufacturing of oligonucleotides for the therapeutic market announced today that Tammy Cooper will be appointed President of...

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...



News published on and distributed by: